Status:
COMPLETED
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Lead Sponsor:
Edgemont Pharmaceuticals, LLC
Conditions:
Generalized Anxiety Disorder (GAD)
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) and confirmed b...
Eligibility Criteria
Inclusion
- Men and women between the ages of 18-65 years and
- Diagnosed with GAD and
- No other psychiatric conditions, and are otherwise medically healthy.
Exclusion
- Women who are pregnant or lactating.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
495 Patients enrolled
Trial Details
Trial ID
NCT02305797
Start Date
January 1 2015
End Date
May 1 2016
Last Update
September 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Investigational Sites
Multiple Locations, California, United States